Reports from Phase 3 study Indicate Significant Market Reports from Phase 3 study Indicate Significant Market

Science and Technology News

Reports from Phase 3 study Indicate Significant Market Opportunity for Avanafil (Nasdaq:VVUS)

Windsor, Alberta 11/18/2009 07:10 PM GMT (TransWorldNews)

VIVUS Announces Positive Results From Phase 3 Study of Avanafil in Erectile Dysfunction; Data Demonstrate Robust Efficacy, Favorable Side-Effect Profile

VIVUS, Inc. (Nasdaq:VVUS) recently reported positive results from REVIVE (TA-301), a phase 3 pivotal study evaluating the safety and efficacy of avanafil, an investigational drug candidate for the treatment of erectile dysfunction (ED), in 646 patients. The REVIVE study met all primary endpoints across the three doses studied by demonstrating statistically significant improvement in erectile function as measured by the Sexual Encounter Profile (SEP) and improvements in the International Index of Erectile Function (IIEF) score. The pivotal study, conducted under a Special Protocol Assessment with the U.S. Food and Drug Administration (FDA), also demonstrated successful intercourse in 30 minutes or less, and a favorable side-effect and safety profile.

Stock Market Weekly, an online financial publication, provides investors timely stock market alerts and news.

Sign Up Today for our Free Stock Newsletter

"Erectile dysfunction is a significant problem among more than half of all men over the age of 40. While sales of currently available ED therapies exceed $3.8 billion a year, persistent switching by patients suggests that patients are less than satisfied with current therapies," stated Leland Wilson, chief executive officer of VIVUS. "These phase 3 avanafil data not only confirm the robust efficacy we've seen in earlier trials, but potentially differentiate avanafil from other PDE5 inhibitors when it comes to side effects and time-to-onset of efficacy. We are confident that avanafil can effectively compete in the oral ED therapy market." VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The company's lead product in clinical development, Qnexa(TM), has recently completed phase 3 clinical trials for the treatment of obesity. Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a potentially best-in-class PDE5 inhibitor, and in phase 2 development of Luramist(TM) for the treatment of hypoactive sexual desire disorder (HSDD) in women. MUSE . (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS.

Sign Up for Stock Market Weekly's FREE Stock Market Today

About Stock Market Weekly

Stock Market Weekly is a financial website and independent electronic publication that provides information and free stock marketing alerts and news on selected publicly traded companies. We also track small cap companies that may be positioned to break out.

Stock Market Weekly is not a registered investment advisor or broker-dealer. Please do your own Due Diligence before investing in any of the stocks mentioned above. To feature a company on our web site please contact us at the email listed below.

admin@stockmarketweekly.com

www.stockmarketweekly.com

NEWS ALERTS

Receive alerts for Stock Market Weekly to your inbox. Sign up for TransWorldNews Alerts

TransWorldNews, Inc. and its affiliate sites disclaim all liability for information and content provided by clients and appearing within their news and press releases.

Stock Quotes

Additional Headlines

Reports from Phase 3 study Indicate Significant Market Opportunity for Avanafil (Nasdaq:VVUS)

Sanmina-SCI (NASDAQ: SAMN) Completes Early Redemption of Its Senior Floating Rate Notes Due 2010

Suntech's (NYSE: STP), CEO Dr. Zhengrong Shi Elected to ATSE Fellowship

Broken IPOD TOUCH 3rd Generation Screen Replacements Now Offered

Verizon (NYSE: VZ) IP Network Improves Bowling Customer Experience, Streamlines IT Operations

Motorola (NYSE: MOT) Expands LTE Solution With New, Frame-Based eNodeB

IPOD Repair Company Ready for Black Friday, Cyber Monday

First Thanksgiving Joining Pilgrims and Native Americans Offers Secrets into Organic Farming

Benchmark Electronics Announce Additional Facilities Are Now Certified to the International Aerospace Quality Group AS9100 Standard

Barker Company to be Acquired by Hill PHOENIX

Copyright 2008, TransWorldNews, Inc. All Rights Reserved. Privacy Policy Legal disclaimer

concept		evidence	hits	links
	$drugwar_propaganda 60% [news] [concept]	$propaganda_theme1 $propaganda_theme3		Classic Modern Drug Propaganda Themes in Chemical Prohibition Drug War Propaganda (book)
	$propaganda_theme1 60% [news] [concept]	"dealer"	1	Hated Groups (propaganda theme 1) http://www.drugwarfacts.org/druguse.htm http://www.drugwarfacts.org/racepris.htm http://www.narcoterror.org/
	$propaganda_theme3 50% [news] [concept]	"Americans"	1	Survival of Society (propaganda theme 3)
	$drugs 90% [news] [concept]	$various_drugs
	$various_drugs 90% [news] [concept]	"drug"	2
	$dea_prime_contractor 80% [news] [concept]	"Motorola"	1	http://drugpolicycentral.com/bot/us_doj_pri...

observer's propaganda picks

See drug-warrior propaganda somewhere?
Submit text or a url, and bot will analyze prohibition propaganda for you!

Prohibition-era cartoons
Anti-prohibition political cartoons from Prohibition I.

Donate to drugsense please give generously!